Get to know our clinical trials
Clinical trial of EO2463 for the treatment of patients with non-Hodgkin's lymphoma of limited malignancy.
THE PURPOSE OF THIS STUDY IS TO ASSESS TOLERABILITY (I.E. HOW POTENTIAL ADVERSE EVENTS ARE TOLERATED) AND SAFETY, AS WELL AS TO DISCOVER THE FIRST DATA ON THE EFFICACY OF THE EXPERIMENTAL DRUG CALLED "EO2463". IN THIS RESEARCH STUDY, EO2463 IS ADMINISTERED TO PATIENTS FOR THE FIRST TIME, SO ANOTHER PURPOSE OF THIS STUDY IS TO DETERMINE THE MOST APPROPRIATE DOSE. THIS NEW DRUG, EO2463, IS A THERAPEUTIC VACCINE DESIGNED TO STIMULATE THE IMMUNE SYSTEM AGAINST CERTAIN TYPES OF CANCER CELLS, UNLIKE CONVENTIONAL VACCINES, WHICH ARE BASICALLY PREVENTIVE IN NATURE.
Technical Summary
- A MULTICENTER, GLOBAL PHASE I/II PHASE I/II STUDY OF EO2463, A NOVEL PEPTIDE THERAPEUTIC VACCINE OF MICROBIAL ORIGIN, IN MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH NON-HODGKIN'S LYMPHOMA OF LOW MALIGNANCY (SIDNEY STUDY). IMMUNOTHERAPY
- Code EudraCT: 2020-003999-40
- Protocol number: EONHL1-20
- Promoter: Enterome Bioscience
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs